Cell MedX Corp. (CMXC) Announces Additional Results of Preliminary Analysis of Metabolomic Assays in Phase 1 Pilot Clinical Trial
LAS VEGAS, NV–Cell MedX Corp. (OTCQB: CMXC), (the “Company”) is pleased to announce additional results of the ongoing analysis of metabolomic assays taken during the Phase 1 pilot clinical trial.
The pilot clinical discovery phase trial in two diabetic subjects was performed in January 2015. Ongoing metabolomic analyses of the samples have yielded additional insights into the immediate metabolic alterations brought about by a single e-balance technology treatment. In addition to indications of increased sensitivity to insulin, glycolytic processes are also clearly upregulated. These new findings reveal enhanced transport as well as utilization of glucose during a treatment.
Further exploration of these pathways will continue, along with sustained treatment end points such as HbA1C, in a formal Phase 1B clinical trial scheduled to take place in Newport Beach, CA. In order to carry out the clinical trial, the Company has started recruiting subjects with Type 1 and Type 2 diabetes.
The analysis of the samples was conducted by The Metabolomics Innovation Centre at the University of Alberta (“TMIC”), whose analytic and informatics toolsets and translational “omics” expertise allows for cost-effective and more accurate results of assays.
About The Metabolomics Innovation Centre:
The Metabolomics Innovation Centre (“TMIC”) is a Genome Canada funded Science & Technology Innovation Centre for metabolomics research, technology development and services. TMIC builds on metabolomics expertise at the University of Alberta and the University of Victoria, which includes $20 million in state-of-the-art metabolomics equipment and ongoing investment for “omics” research and technologies by Genome Canada, Genome British Columbia and Genome Alberta. TMIC’s technologies are based on NMR, mass spectrometry, gas chromatography and novel bioinformatics tools to support clinical trial research, biomedical studies, agricultural studies, nutrient profiling and environmental testing for applications such as human health and disease, petroleum research, forensics, food and nutrition, anti-doping, and textile sciences. TMIC provides access to cutting-edge metabolomic and bioinformatics technologies for Genome Canada-funded projects and the broader research community including government, academia and industry. For more information, visit www.metabolomicscentre.ca.
About Cell MedX Corp.:
Cell MedX Corp. is an early development stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes by developing technologies to help manage the illness and related complications. Through its wholly owned subsidiary, Avyonce Cosmedics Inc., Cell MedX Corp. is engaged in reselling and marketing of spa technology and equipment to the worldwide beauty and wellness industry as well as providing continuing education to the estheticians and health care professionals in the field of medical aesthetics.
On behalf of the Board of Directors of Cell MedX Corp.
Frank McEnulty
Chief Executive Officer and President.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company’s e-balance Technology is still in development. The Company does not currently have any commercially marketable products based on the e-balance Technology, and there is no assurance that the Company will be successful in its development efforts. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.